home / stock / fixx / fixx news

FIXX News and Press, Homology Medicines Inc. From 02/20/19

Stock Information
Company Name: Homology Medicines Inc.
Stock Symbol: FIXX
Market: NASDAQ
Website: homologymedicines.com
Menu
FIXX FIXX Quote FIXX Short FIXX News FIXX Articles FIXX Message Board
Get FIXX Alerts

News, Short Squeeze, Breakout and More Instantly...
FIXX - Chardan likes Kodiak Sciences in premarket analyst action

OrthoPediatrics (NASDAQ: KIDS ) initiated with Outperform rating and $44 (17% upside) price target at JMP Securities. More news on: OrthoPediatrics Corp., Homology Medicines, Kodiak Sciences, Healthcare stocks news, Stocks on the move, , Read more ...

FIXX - Homology Medicines Achieves 2018 Goals and Prepares PKU Gene Therapy Program for the Clinic with Initial Data Expected in 2019

- Two Additional Programs Advance to IND-Enabling Studies, Including First Gene Editing Program and a CNS Gene Therapy - - Homology’s New GMP Manufacturing Facility Preparing for Production at 500 Liter Scale - - Orphan Drug Designation Granted for HMI-102 PKU Gene Ther...

FIXX - Homology Medicines Advances First Gene Editing Development Candidate into IND-Enabling Studies for Pediatric Patients with Phenylketonuria

- Data Demonstrates Highly Efficient and Selective In Vivo Gene Editing in a Humanized Murine Model - - New Internal GMP Manufacturing Capability to Support Gene Therapy and Gene Editing Programs - BEDFORD, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (N...

FIXX - Homology Medicines Presents Data on Platform's Ability to Target the Central and Peripheral Nervous System and Therapeutic Potential in the Rare Disease Metachromatic Leukodystrophy

Homology to Nominate a Clinical Development Candidate for MLD This Quarter and to Begin IND-Enabling Studies in 2019 BEDFORD, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today data demonstrating that Homology&#...
FIXX - Biotech IPOs on pace for near-record year - WSJ

The Wall Street Journal reports that the pace of biotech IPOs in on track for a near-record year, although many are riskier due to being in earlier stages of development. The public funding rush has been heavily influenced by the FDA's willingness to accelerate approval for promising drugs...

Previous 10 Next 10